FORM 10-Q
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
SORRENTO THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
33-0344842
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification Number)
|
(858) 203-4100
(Registrant’s Telephone Number, Including Area Code)
|
Large accelerated filer
|
|
x
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
|||
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
|
|
|
|
Title of each class:
|
|
Trading Symbol (s)
|
|
Name of each exchange on which registered:
|
Common Stock, $0.0001 par value
|
|
SRNE
|
|
The Nasdaq Stock Market LLC
|
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
ASSETS
|
March 31,
2019 |
|
December 31,
2018 |
||||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
90,971
|
|
|
$
|
158,738
|
|
Restricted Cash
|
9,592
|
|
|
9,592
|
|
||
Marketable securities
|
391
|
|
|
297
|
|
||
Grants and accounts receivables, net
|
7,409
|
|
|
3,833
|
|
||
Inventory
|
4,568
|
|
|
2,898
|
|
||
Income tax receivable
|
193
|
|
|
526
|
|
||
Prepaid expenses and other
|
5,455
|
|
|
3,680
|
|
||
Total current assets
|
118,579
|
|
|
179,564
|
|
||
Property and equipment, net
|
28,900
|
|
|
24,384
|
|
||
Operating lease right-of-use assets
|
43,292
|
|
|
—
|
|
||
Intangibles, net
|
65,817
|
|
|
66,283
|
|
||
Goodwill
|
38,298
|
|
|
38,298
|
|
||
Cost method investments
|
237,008
|
|
|
237,008
|
|
||
Equity method investments
|
27,083
|
|
|
27,980
|
|
||
Restricted cash
|
45,150
|
|
|
45,000
|
|
||
Other, net
|
5,347
|
|
|
5,570
|
|
||
Total assets
|
$
|
609,474
|
|
|
$
|
624,087
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
14,652
|
|
|
$
|
13,817
|
|
Accrued payroll and related benefits
|
10,159
|
|
|
10,236
|
|
||
Accrued expenses
|
23,590
|
|
|
13,403
|
|
||
Current portion of deferred revenue
|
3,157
|
|
|
2,703
|
|
||
Acquisition consideration payable
|
11,312
|
|
|
11,312
|
|
||
Current portion of debt
|
8,678
|
|
|
10,150
|
|
||
Current portion of operating lease liabilities
|
2,534
|
|
|
—
|
|
||
Total current liabilities
|
74,082
|
|
|
61,621
|
|
||
Long-term debt, net of discount
|
229,662
|
|
|
223,136
|
|
||
Deferred tax liabilities, net
|
9,230
|
|
|
9,416
|
|
||
Deferred revenue
|
115,501
|
|
|
116,274
|
|
||
Derivative liability
|
14,501
|
|
|
—
|
|
||
Operating lease liabilities
|
47,628
|
|
|
—
|
|
||
Deferred rent and other
|
757
|
|
|
6,140
|
|
||
Total liabilities
|
491,361
|
|
|
416,587
|
|
||
Commitments and contingencies (See Note 14)
|
|
|
|
|
|
||
Equity:
|
|
|
|
|
|
||
Sorrento Therapeutics, Inc. equity
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding
|
—
|
|
|
—
|
|
||
Common stock, $0.0001 par value 750,000,000 shares authorized and 122,311,917 and 122,280,092 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
|
13
|
|
|
13
|
|
||
Additional paid-in capital
|
657,115
|
|
|
626,658
|
|
||
Accumulated other comprehensive income
|
100
|
|
|
15
|
|
||
Accumulated deficit
|
(475,821
|
)
|
|
(367,750
|
)
|
||
Treasury stock, 7,568,182 shares at cost at March 31, 2019, and December 31, 2018
|
(49,464
|
)
|
|
(49,464
|
)
|
||
Total Sorrento Therapeutics, Inc. stockholders' equity
|
131,943
|
|
|
209,472
|
|
||
Noncontrolling interests
|
(13,830
|
)
|
|
(1,972
|
)
|
||
Total equity
|
118,113
|
|
|
207,500
|
|
||
Total liabilities and stockholders' equity
|
$
|
609,474
|
|
|
$
|
624,087
|
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
|
|
|
|
||||
Revenues:
|
|
|
|
|
|
||
Royalty and license
|
$
|
120
|
|
|
$
|
120
|
|
Sales and services
|
6,023
|
|
|
6,126
|
|
||
Total revenues
|
6,143
|
|
|
6,246
|
|
||
Operating costs and expenses:
|
|
|
|
|
|
||
Costs of revenues
|
2,308
|
|
|
1,311
|
|
||
Research and development
|
25,584
|
|
|
14,632
|
|
||
Acquired in-process research and development
|
75,301
|
|
|
—
|
|
||
General and administrative
|
25,122
|
|
|
9,961
|
|
||
Intangible amortization
|
966
|
|
|
662
|
|
||
Loss on contingent liabilities
|
32
|
|
|
12,226
|
|
||
Total operating costs and expenses
|
129,313
|
|
|
38,792
|
|
||
Loss from operations
|
(123,170
|
)
|
|
(32,546
|
)
|
||
Gain on trading securities
|
94
|
|
|
3
|
|
||
Loss on derivative liability
|
(14,501
|
)
|
|
—
|
|
||
Gain on foreign currency exchange
|
313
|
|
|
17
|
|
||
Interest expense
|
(9,080
|
)
|
|
(1,052
|
)
|
||
Interest income
|
534
|
|
|
4
|
|
||
Loss before income tax
|
(145,810
|
)
|
|
(33,574
|
)
|
||
Income tax benefit
|
(178
|
)
|
|
(948
|
)
|
||
Loss on equity method investments
|
(897
|
)
|
|
(922
|
)
|
||
Net loss
|
(146,529
|
)
|
|
(33,548
|
)
|
||
Net loss attributable to noncontrolling interests
|
(38,458
|
)
|
|
(974
|
)
|
||
Net loss attributable to Sorrento
|
$
|
(108,071
|
)
|
|
$
|
(32,574
|
)
|
Net loss per share - basic per share attributable to Sorrento
|
$
|
(0.88
|
)
|
|
$
|
(0.38
|
)
|
Net loss per share - diluted per share attributable to Sorrento
|
$
|
(0.88
|
)
|
|
$
|
(0.38
|
)
|
Weighted-average shares used during period - basic per share attributable to Sorrento
|
122,281
|
|
|
84,941
|
|
||
Weighted-average shares used during period - diluted per share attributable to Sorrento
|
122,281
|
|
|
84,941
|
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
|
|
|
|
||||
Net loss
|
(146,529
|
)
|
|
$
|
(33,548
|
)
|
|
Other comprehensive gain:
|
|
|
|
|
|
||
Foreign currency translation adjustments
|
85
|
|
|
110
|
|
||
Total other comprehensive loss
|
85
|
|
|
110
|
|
||
Comprehensive loss
|
(146,444
|
)
|
|
(33,438
|
)
|
||
Comprehensive loss attributable to noncontrolling interests
|
(38,458
|
)
|
|
(974
|
)
|
||
Comprehensive loss attributable to Sorrento
|
$
|
(107,986
|
)
|
|
$
|
(32,464
|
)
|
|
Three Months Ended March 31, 2019
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Common Stock
|
|
Treasury Stock
|
|
Additional
Paid-in Capital
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Accumulated
Deficit
|
|
Noncontrolling
Interest
|
|
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
|
|
Total
|
|||||||||||||||||||||
Balance, December 31, 2018
|
122,280,092
|
|
|
$
|
13
|
|
|
7,568,182
|
|
|
(49,464
|
)
|
|
$
|
626,658
|
|
|
$
|
15
|
|
|
$
|
(367,750
|
)
|
|
$
|
(1,972
|
)
|
|
$
|
207,500
|
|
|
Issuance of common stock upon exercise of stock options
|
31,825
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
81
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
81
|
|
|||||||
Equity contribution related to Semnur acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
28,400
|
|
|
—
|
|
|
—
|
|
|
26,600
|
|
|
55,000
|
|
|||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,976
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,976
|
|
|||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
85
|
|
|
|
|
|
—
|
|
|
85
|
|
|||||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(108,071
|
)
|
|
(38,458
|
)
|
|
(146,529
|
)
|
|||||||
Balance, March 31, 2019
|
122,311,917
|
|
|
$
|
13
|
|
|
7,568,182
|
|
|
$
|
(49,464
|
)
|
|
$
|
657,115
|
|
|
$
|
100
|
|
|
$
|
(475,821
|
)
|
|
$
|
(13,830
|
)
|
|
$
|
118,113
|
|
|
Three Months Ended March 31, 2018
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Common Stock
|
|
Treasury Stock
|
|
Additional
Paid-in Capital
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Accumulated
Deficit
|
|
Noncontrolling
Interest
|
|
|
||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
|
|
Total
|
|||||||||||||||||||||
Balance, December 31, 2017
|
82,903,567
|
|
|
$
|
9
|
|
|
7,568,182
|
|
|
(49,464
|
)
|
|
$
|
413,901
|
|
|
$
|
242
|
|
|
$
|
(165,120
|
)
|
|
$
|
7,042
|
|
|
$
|
206,610
|
|
|
Adoption impact of ASC 606
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
910
|
|
|
—
|
|
|
910
|
|
|||||||
Issuance of common stock upon exercise of stock options
|
24,090
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
155
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
155
|
|
|||||||
Issuance of common stock for BDL settlement
|
309,916
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,340
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,340
|
|
|||||||
Issuance of common stock for Scilex settlement
|
1,381,346
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
13,744
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
13,744
|
|
|||||||
Issuance of common stock for public placement and investments, net
|
6,409,170
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
48,957
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
48,958
|
|
|||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,594
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,594
|
|
|||||||
Foreign currency translation adjustment
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
110
|
|
|
—
|
|
|
—
|
|
|
110
|
|
|||||||
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(32,574
|
)
|
|
(974
|
)
|
|
(33,548
|
)
|
|||||||
Balance, March 31, 2018
|
91,028,089
|
|
|
$
|
10
|
|
|
7,568,182
|
|
|
$
|
(49,464
|
)
|
|
$
|
480,691
|
|
|
$
|
352
|
|
|
$
|
(196,784
|
)
|
|
$
|
6,068
|
|
|
$
|
240,873
|
|
|
Three Months Ended March 31,
|
||||||
Operating activities
|
2019
|
|
2018
|
||||
Net loss
|
$
|
(146,529
|
)
|
|
$
|
(33,548
|
)
|
Adjustments to reconcile net loss to net cash used for operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
3,038
|
|
|
2,005
|
|
||
Amortization of operating lease right-of-use assets
|
1,292
|
|
|
—
|
|
||
Non-cash interest expense
|
5,682
|
|
|
288
|
|
||
Loss on disposals
|
433
|
|
|
—
|
|
||
Semnur-related IPR&D
|
75,301
|
|
|
—
|
|
||
Amortization of debt issuance costs
|
518
|
|
|
1
|
|
||
Gain on trading securities
|
(94
|
)
|
|
(3
|
)
|
||
Stock-based compensation
|
1,976
|
|
|
1,594
|
|
||
Loss on derivative liability
|
14,501
|
|
|
—
|
|
||
Loss on equity method investments
|
897
|
|
|
922
|
|
||
Loss on contingent liabilities and acquisition consideration payable
|
32
|
|
|
12,226
|
|
||
Deferred tax provision
|
(186
|
)
|
|
(895
|
)
|
||
Changes in operating assets and liabilities, excluding effect of acquisitions:
|
|
|
|
|
|
||
Grants and other receivables
|
(3,575
|
)
|
|
(1,701
|
)
|
||
Accrued payroll
|
(76
|
)
|
|
19
|
|
||
Prepaid expenses and other
|
(2,989
|
)
|
|
(1,286
|
)
|
||
Deposits and other assets
|
406
|
|
|
113
|
|
||
Accounts payable
|
(3,439
|
)
|
|
(1,825
|
)
|
||
Deferred revenue
|
(319
|
)
|
|
(1,378
|
)
|
||
Other
|
163
|
|
|
(33
|
)
|
||
Acquisition consideration payable for Scilex
|
—
|
|
|
(2,020
|
)
|
||
Accrued expenses and other liabilities
|
8,659
|
|
|
1,558
|
|
||
Net cash used in operating activities
|
(44,309
|
)
|
|
(23,963
|
)
|
||
Investing activities
|
|
|
|
|
|
||
Purchases of property and equipment
|
(5,228
|
)
|
|
(448
|
)
|
||
Purchase of assets related to Semnur
|
(17,040
|
)
|
|
—
|
|
||
Net cash used in investing activities
|
(22,268
|
)
|
|
(448
|
)
|
||
Financing activities
|
|
|
|
|
|
||
Proceeds from bridge loan for Scilex regulatory milestone
|
—
|
|
|
20,000
|
|
||
Repayment of bridge loan for Scilex regulatory milestone
|
—
|
|
|
(20,000
|
)
|
||
Proceeds from loan agreement
|
—
|
|
|
1,586
|
|
||
Short-term loan repayment
|
(740
|
)
|
|
—
|
|
||
Scilex consideration for regulatory milestone
|
—
|
|
|
(22,466
|
)
|
||
Payment on Scilex Notes
|
(438
|
)
|
|
—
|
|
||
Proceeds from issuance of common stock, net
|
—
|
|
|
48,958
|
|
||
Proceeds from exercise of stock options
|
81
|
|
|
155
|
|
||
Net cash (used in) provided by financing activities
|
(1,097
|
)
|
|
28,233
|
|
||
Net change in cash, cash equivalents and restricted cash
|
(67,674
|
)
|
|
3,822
|
|
||
Net effect of exchange rate changes on cash
|
57
|
|
|
1
|
|
||
Cash, cash equivalents and restricted cash at beginning of period
|
213,330
|
|
|
20,429
|
|
Cash, cash equivalents and restricted cash at end of period
|
$
|
145,713
|
|
|
$
|
24,252
|
|
Supplemental disclosures:
|
|
|
|
|
|
||
Cash paid during the period for:
|
|
|
|
|
|
||
Interest paid
|
$
|
2,505
|
|
|
$
|
128
|
|
Supplemental disclosures of non-cash investing and financing activities:
|
|
|
|
|
|
||
Semnur non-cash consideration
|
$
|
55,000
|
|
|
$
|
—
|
|
BDL non-cash consideration
|
$
|
—
|
|
|
$
|
2,340
|
|
Property and equipment costs incurred but not paid
|
$
|
1,531
|
|
|
$
|
965
|
|
Scilex non-cash consideration for regulatory milestone
|
$
|
—
|
|
|
$
|
13,744
|
|
Reconciliation of cash, cash equivalents and restricted cash within the Company’s consolidated balance sheets:
|
|
|
|
||||
Cash and cash equivalents
|
90,971
|
|
|
24,252
|
|
||
Restricted cash
|
54,742
|
|
|
—
|
|
||
Cash, cash equivalents, and restricted cash
|
$
|
145,713
|
|
|
$
|
24,252
|
|
•
|
Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
|
•
|
Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.
|
•
|
Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
|
|
Three Months Ended March 31,
|
||||||
|
March 31, 2019
|
|
March 31, 2018
|
||||
Scilex product sales
|
$
|
2,859
|
|
|
$
|
—
|
|
Concortis sales and services
|
1,810
|
|
|
1,463
|
|
||
Materials and supply agreements
|
500
|
|
|
861
|
|
||
Bioserv sales and services
|
854
|
|
|
2,135
|
|
||
Joint development agreement
|
—
|
|
|
1,667
|
|
||
|
$
|
6,023
|
|
|
$
|
6,126
|
|
|
|
Remainder of 2019
|
|
2020
|
|
2021 and thereafter
|
Contract manufacturing services
|
|
$705
|
|
$407
|
|
$131
|
|
Fair Value Measurements at March 31, 2019
|
||||||||||||||
|
Balance
|
|
Quoted Prices in Active Markets (Level 1)
|
|
Significant Other Observable Inputs (Level 2)
|
|
Significant Unobservable Inputs (Level 3)
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
$
|
90,971
|
|
|
$
|
90,971
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restricted cash
|
54,742
|
|
|
54,742
|
|
|
—
|
|
|
—
|
|
||||
Marketable securities
|
391
|
|
|
316
|
|
|
—
|
|
|
75
|
|
||||
Total assets
|
$
|
146,104
|
|
|
$
|
146,029
|
|
|
$
|
—
|
|
|
$
|
75
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Derivative liability
|
$
|
14,501
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
14,501
|
|
Acquisition consideration payable
|
11,312
|
|
|
—
|
|
|
—
|
|
|
11,312
|
|
||||
Acquisition consideration payable - Non-current
|
757
|
|
|
—
|
|
|
—
|
|
|
757
|
|
||||
Total liabilities
|
$
|
26,570
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
26,570
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fair Value Measurements at December 31, 2018
|
||||||||||||||
|
Balance
|
|
Quoted Prices in Active Markets (Level 1)
|
|
Significant Other Observable Inputs (Level 2)
|
|
Significant Unobservable Inputs (Level 3)
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
$
|
158,738
|
|
|
$
|
158,738
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restricted cash
|
54,592
|
|
|
54,592
|
|
|
—
|
|
|
—
|
|
||||
Marketable securities
|
297
|
|
|
247
|
|
|
—
|
|
|
50
|
|
||||
Total assets
|
$
|
213,627
|
|
|
$
|
213,577
|
|
|
$
|
—
|
|
|
$
|
50
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Acquisition consideration payable
|
$
|
11,312
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
11,312
|
|
Acquisition consideration payable - Non-current
|
725
|
|
|
—
|
|
|
—
|
|
|
725
|
|
||||
Total liabilities
|
$
|
12,037
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
12,037
|
|
(in thousands)
|
|
Fair Value
|
||
Beginning Balance at December 31, 2018
|
|
$
|
12,037
|
|
Re-measurement of Fair Value
|
|
32
|
|
|
Ending Balance at March 31, 2019
|
|
$
|
12,069
|
|
(in thousands)
|
|
Fair Value Measurements at March 31, 2019
|
|
Valuation Methodology
|
|
Significant Unobservable Input
|
|
Weighted Average
(range, if applicable)
|
||
Virttu Contingent Consideration (Non-current)
|
|
$
|
757
|
|
|
Multiple outcome
discounted cash flow
|
|
Discount Rate
Probability of Regulatory Milestone
|
|
19.2%
16% |
Concortis Contingent Consideration
|
|
$
|
511
|
|
|
Multiple outcome
discounted cash flow
|
|
Discount Rate
Percent probabilities assigned to scenarios
|
|
19.2%
20% |
Shanghai Three Contingent Consideration
|
|
$
|
336
|
|
|
Multiple outcome
discounted cash flow
|
|
Discount Rate
Percent probabilities assigned to scenarios
|
|
19.2%
10% |
RWMC Contingent Consideration
|
|
$
|
503
|
|
|
Multiple outcome
discounted cash flow
|
|
Discount Rate,
Percent probabilities assigned to scenarios
|
|
19.2%
10% |
(in thousands)
|
|
Fair Value
|
||
Beginning Balance at December 31, 2018
|
|
$
|
—
|
|
Re-measurement of Fair Value
|
|
14,501
|
|
|
Ending Balance at March 31, 2019
|
|
$
|
14,501
|
|
|
March 31, 2019
|
||||||||||
|
Cost
|
|
Gross Realized Gains (Losses)
|
|
Fair Value
|
||||||
Trading securities:
|
|
|
|
|
|
|
|
|
|||
MedoveX common shares and warrants
|
$
|
750
|
|
|
$
|
(359
|
)
|
|
$
|
391
|
|
|
December 31, 2018
|
||||||||||
|
Cost
|
|
Gross Realized Gains (Losses)
|
|
Fair Value
|
||||||
Trading securities:
|
|
|
|
|
|
|
|
|
|||
MedoveX common shares and warrants
|
$
|
750
|
|
|
$
|
(453
|
)
|
|
$
|
297
|
|
|
Total
|
||
Beginning balance at December 31, 2018
|
$
|
50
|
|
Change in fair value of warrant
|
25
|
|
|
Ending balance at March 31, 2019
|
$
|
75
|
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Furniture and fixtures
|
$
|
1,239
|
|
|
$
|
1,127
|
|
Office equipment
|
665
|
|
|
632
|
|
||
Machinery and lab equipment
|
28,766
|
|
|
27,690
|
|
||
Leasehold improvements
|
9,101
|
|
|
9,001
|
|
||
Construction in progress
|
6,488
|
|
|
1,221
|
|
||
|
46,259
|
|
|
39,671
|
|
||
Less accumulated depreciation
|
(17,359
|
)
|
|
(15,287
|
)
|
||
|
$
|
28,900
|
|
|
$
|
24,384
|
|
|
Total
|
||
Balance at December 31, 2018
|
$
|
38,298
|
|
Goodwill Acquired from Acquisitions
|
—
|
|
|
Balance at March 31, 2019
|
$
|
38,298
|
|
|
March 31, 2019
|
||||||||||
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Intangibles, net
|
||||||
Customer relationships
|
$
|
1,585
|
|
|
$
|
1,380
|
|
|
$
|
205
|
|
Acquired technology
|
3,410
|
|
|
929
|
|
|
2,481
|
|
|||
Acquired in-process research and development
|
35,834
|
|
|
731
|
|
|
35,103
|
|
|||
Patent rights
|
32,720
|
|
|
5,287
|
|
|
27,433
|
|
|||
Assembled workforce
|
$
|
605
|
|
|
$
|
10
|
|
|
$
|
595
|
|
Total intangible assets
|
$
|
74,154
|
|
|
$
|
8,337
|
|
|
$
|
65,817
|
|
|
December 31, 2018
|
||||||||||
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Intangibles, net
|
||||||
Customer relationships
|
$
|
1,585
|
|
|
$
|
1,373
|
|
|
$
|
212
|
|
Acquired technology
|
3,410
|
|
|
885
|
|
|
2,525
|
|
|||
Acquired in-process research and development
|
35,834
|
|
|
366
|
|
|
35,468
|
|
|||
Patent rights
|
32,720
|
|
|
4,742
|
|
|
27,978
|
|
|||
Assembled workforce
|
105
|
|
|
5
|
|
|
100
|
|
|||
Total intangible assets
|
$
|
73,654
|
|
|
$
|
7,371
|
|
|
$
|
66,283
|
|
Years Ending December 31,
|
|
Amount
|
||
2019 (Remaining nine months)
|
|
$
|
2,152
|
|
2020
|
|
2,869
|
|
|
2021
|
|
3,923
|
|
|
2022
|
|
3,923
|
|
|
2023
|
|
3,918
|
|
|
2024
|
|
3,827
|
|
|
Thereafter
|
|
45,205
|
|
|
Total expected future amortization
|
|
$
|
65,817
|
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Face value of loan
|
$
|
37,849
|
|
|
$
|
37,849
|
|
Unamortized debt discount
|
(14,289
|
)
|
|
(14,804
|
)
|
||
Accretion of debt discount
|
538
|
|
|
515
|
|
||
Ending balance
|
$
|
24,098
|
|
|
$
|
23,560
|
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Face value of loan
|
$
|
224,000
|
|
|
$
|
224,000
|
|
Unamortized debt discount
|
(77,624
|
)
|
|
(84,000
|
)
|
||
Capitalized debt issuance costs
|
(5,313
|
)
|
|
(5,748
|
)
|
||
Accretion of debt discount
|
4,326
|
|
|
6,376
|
|
||
Amortization of debt issuance cost
|
299
|
|
|
435
|
|
||
Payments
|
(438
|
)
|
|
—
|
|
||
Ending balance
|
$
|
145,250
|
|
|
$
|
141,063
|
|
Year Ending December 31,
|
|
||
2019 (Remaining nine months)
|
$
|
3,912
|
|
2020
|
17,770
|
|
|
2021
|
31,283
|
|
|
2022
|
73,007
|
|
|
2023
|
97,590
|
|
|
Total future minimum payments
|
223,562
|
|
|
Unamortized debt discount
|
(73,298
|
)
|
|
Unamortized capitalized debt issuance costs
|
(5,014
|
)
|
|
Total minimum payment
|
145,250
|
|
|
Current portion
|
(7,933
|
)
|
|
Long-term portion of Scilex Notes
|
$
|
137,317
|
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Face value of loan
|
$
|
100,000
|
|
|
$
|
100,000
|
|
Debt discount - warrant
|
(26,248
|
)
|
|
(26,659
|
)
|
||
Capitalized debt issuance costs
|
(6,543
|
)
|
|
(6,658
|
)
|
||
Accretion of debt discount and amortization of issuance costs
|
1,039
|
|
|
526
|
|
||
Ending balance
|
$
|
68,248
|
|
|
$
|
67,209
|
|
|
Options
Outstanding
|
|
Weighted-
Average
Exercise Price
|
|
Aggregate
Intrinsic
Value
|
|||||
Outstanding at December 31, 2018
|
10,523,075
|
|
|
$
|
4.91
|
|
|
$
|
1,723
|
|
Options Granted
|
—
|
|
|
$
|
—
|
|
|
|
|
|
Options Canceled
|
(302,675
|
)
|
|
$
|
2.03
|
|
|
|
|
|
Options Exercised
|
(34,950
|
)
|
|
$
|
6.46
|
|
|
|
|
|
Outstanding at March 31, 2019
|
10,185,450
|
|
|
|
|
|
$
|
10,253
|
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Weighted-average grant date fair value
|
$
|
—
|
|
|
$
|
7.25
|
|
Dividend yield
|
—
|
%
|
|
—
|
%
|
||
Volatility
|
100
|
%
|
|
81
|
%
|
||
Risk-free interest rate
|
2.42
|
%
|
|
2.49
|
%
|
||
Expected life of options
|
6.1 years
|
|
|
6.1 years
|
|
Common stock warrants outstanding under the loan and security agreements
|
6,354,877
|
|
Common stock warrants outstanding under the Hercules securities agreement
|
306,748
|
|
Common stock warrants outstanding under the convertible notes
|
14,819,872
|
|
Common stock warrants outstanding under private placements
|
4,153,620
|
|
Common stock options outstanding under the Non-Employee Director Plan
|
3,200
|
|
Authorized for future grant or issuance under the 2009 Stock Incentive Plan
|
18,289,456
|
|
Shares issuable upon the conversion of the 2018 Notes
|
5,397,325
|
|
Issuable under assignment agreement based upon achievement of certain milestones
|
80,000
|
|
|
49,405,098
|
|
•
|
An arbitration demand with the American Arbitration Association in Los Angeles, California against NantPharma, LLC and Chief Executive Officer Patrick Soon-Shiong, seeking damages in excess of
$1 billion
, as well as additional punitive damages, related to alleged fraud and breaches of the Stock Sale and Purchase Agreement, dated May 14, 2015, entered into between NantPharma LLC and the Company, included as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2015. The Company makes no representations as to the likely success or outcome of such arbitration; and
|
•
|
An action in the Los Angeles Superior Court derivatively on behalf of Immunotherapy NANTibody LLC (“NANTibody”) against NantCell, Inc., NANTibody Board Member and NantCell, Inc. Chief Executive Officer Patrick Soon-Shiong, and NANTibody officer Charles Kim, related to several breaches of the June 11, 2015 Limited Liability Company Agreement for NANTibody entered into between the Company and NantCell, Inc. The suit also alleges breaches of fiduciary duties and seeks, inter alia, a declaration that the Assignment Agreement entered into on July 2, 2017, between NantPharma, LLC and NANTibody is void and an equitable unwinding of the Assignment Agreement. The suit calls for the restoration of
$90.05 million
to the NANTibody capital account, thereby restoring the Company’s equity method investment in NANTibody to its invested amount as of June 30, 2017 amount of
$40 million
. The Company makes no representations as to the likely success or outcome of such lawsuit.
|
Operating leases
|
Three months ended March 31, 2019
|
||
Long term operating lease costs
|
$
|
2,300
|
|
Short term operating lease costs
|
4
|
|
|
Total operating leases costs
|
$
|
2,304
|
|
|
Three months ended March 31, 2019
|
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|
|
Operating cash flows from operating leases
|
1,533
|
|
|
|
|
Right-of-use assets obtained in exchange for new operating lease liabilities
|
300
|
|
|
|
|
Weighted average remaining lease term in years - operating leases
|
9.9 years
|
|
Weighted average discount rate - operating leases
|
12.1
|
%
|
Years ending December 31,
|
Operating leases
|
||
2019 (Remaining nine months)
|
$
|
5,319
|
|
2020
|
9,153
|
|
|
2021
|
8,448
|
|
|
2022
|
8,496
|
|
|
2023
|
8,186
|
|
|
2024
|
8,374
|
|
|
Thereafter
|
42,117
|
|
|
Total lease payments
|
90,093
|
|
|
Less imputed interest
|
(39,931
|
)
|
|
Total lease liabilities as of March 31, 2019
|
$
|
50,162
|
|
2019
|
$
|
6,396
|
|
2020
|
8,733
|
|
|
2021
|
8,011
|
|
|
2022
|
7,959
|
|
|
2023
|
8,186
|
|
|
Thereafter
|
52,425
|
|
|
|
$
|
91,710
|
|
|
Three Months Ended March 31,
|
||||||
|
2019
|
|
2018
|
||||
Basic and Diluted
|
|
|
|
|
|
||
Net loss attributable to Sorrento
|
$
|
(108,071
|
)
|
|
$
|
(32,574
|
)
|
|
|
|
|
||||
Denominator for Basic Loss Per Share
|
122,281
|
|
|
84,941
|
|
||
Denominator for Diluted Loss Per Share
|
122,281
|
|
|
84,941
|
|
||
Basic Loss Per Share
|
$
|
(0.88
|
)
|
|
$
|
(0.38
|
)
|
Diluted Loss Per Share
|
$
|
(0.88
|
)
|
|
$
|
(0.38
|
)
|
•
|
In October 2018, Scilex commercially launched its ZTlido® (lidocaine topical system 1.8%) product and began recognizing revenue in the fourth quarter of 2018.
|
•
|
Semnur’s SP-102 compound is the first non-opioid corticosteroid formulated as a viscous gel injection in development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. SP-102 has been awarded fast track status by the FDA. See Note 4 for further detail on the Semnur acquisition.
|
|
Three months ended March 31,
|
||||||||||||||||||
|
2019
|
|
2018
|
||||||||||||||||
(in thousands)
|
Sorrento Therapeutics
|
Scilex
|
Total
|
|
Sorrento Therapeutics
|
Scilex
|
Total
|
||||||||||||
External revenues
|
$
|
3,284
|
|
$
|
2,859
|
|
$
|
6,143
|
|
|
$
|
6,246
|
|
$
|
—
|
|
$
|
6,246
|
|
Operating expenses
|
35,131
|
|
94,182
|
|
129,313
|
|
|
35,702
|
|
3,090
|
|
38,792
|
|
||||||
Operating loss before interest and taxes
|
(31,847
|
)
|
(91,323
|
)
|
(123,170
|
)
|
|
(29,456
|
)
|
(3,090
|
)
|
(32,546
|
)
|
•
|
An arbitration demand with the American Arbitration Association in Los Angeles, California against NantPharma, LLC and Chief Executive Officer Patrick Soon-Shiong, seeking damages in excess of $1 billion, as well as additional punitive damages, related to alleged fraud and breaches of the Stock Sale and Purchase Agreement, dated May 14, 2015, entered into between NantPharma LLC and us, included as Exhibit 10.2 to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2015. We make no representations as to the likely success or outcome of such arbitration; and
|
•
|
An action in the Los Angeles Superior Court derivatively on behalf of Immunotherapy NANTibody LLC (“NANTibody”) against NantCell, Inc., NANTibody Board Member and NantCell, Inc. Chief Executive Officer Patrick Soon-Shiong, and NANTibody officer Charles Kim, related to several breaches of the June 11, 2015 Limited Liability Company Agreement for NANTibody entered into between us and NantCell, Inc. The suit also alleges breaches of fiduciary duties and seeks, inter alia, a declaration that the Assignment Agreement entered into on July 2, 2017, between NantPharma, LLC and NANTibody is void and an equitable unwinding of the Assignment Agreement. The suit calls for the restoration of $90.05 million to the NANTibody capital account, thereby restoring our equity method investment in NANTibody to its invested amount as of June 30, 2017 amount of $40 million. We make no representations as to the likely success or outcome of such lawsuit.
|
•
|
the progress of the development of our fully-human mAbs, including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from our proprietary G-MAB™ library platform, ADCs, BsAbs, as well as CAR-T for adoptive cellular immunotherapy, RTX, ZTlido® (lidocaine topical system 5.4%) and SP-102;
|
•
|
the number of product candidates we pursue;
|
•
|
the time and costs involved in obtaining regulatory approvals;
|
•
|
the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims;
|
•
|
our plans to establish sales, marketing and/or manufacturing capabilities;
|
•
|
the effect of competing technological and market developments;
|
•
|
the terms and timing of any collaborative, licensing and other arrangements that we may establish;
|
•
|
general market conditions for offerings from biopharmaceutical companies;
|
•
|
our ability to establish, enforce and maintain selected strategic alliances and activities required for product commercialization;
|
•
|
our obligations under our debt arrangements; and
|
•
|
our revenues, if any, from successful development and commercialization of our product candidates, including
ZTlido®
(lidocaine topical system 1.8%).
|
•
|
actual or anticipated adverse results or delays in our clinical trials;
|
•
|
our failure to commercialize our product candidates, if approved;
|
•
|
unanticipated serious safety concerns related to the use of any of our product candidates;
|
•
|
adverse regulatory decisions;
|
•
|
changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;
|
•
|
legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation;
|
•
|
our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial;
|
•
|
our dependence on third parties, including CROs;
|
•
|
announcements of the introduction of new products by our competitors;
|
•
|
market conditions in the pharmaceutical and biotechnology sectors;
|
•
|
announcements concerning product development results or intellectual property rights of others;
|
•
|
future issuances of common stock or other securities;
|
•
|
the addition or departure of key personnel;
|
•
|
failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;
|
•
|
actual or anticipated variations in quarterly operating results;
|
•
|
our failure to meet or exceed the estimates and projections of the investment community;
|
•
|
overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;
|
•
|
conditions or trends in the biotechnology and biopharmaceutical industries;
|
•
|
introduction of new products offered by us or our competitors;
|
•
|
announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;
|
•
|
issuances of debt or equity securities;
|
•
|
sales of our common stock by us or our stockholders in the future;
|
•
|
trading volume of our common stock;
|
•
|
ineffectiveness of our internal controls;
|
•
|
publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;
|
•
|
failure to effectively integrate the acquired companies’ operations;
|
•
|
general political and economic conditions;
|
•
|
effects of natural or man-made catastrophic events; and
|
•
|
other events or factors, many of which are beyond our control.
|
2.1+
|
|
|
|
|
|
3.1
|
|
|
|
|
|
4.1
|
|
|
|
|
|
4.2
|
|
|
|
|
|
4.3
|
|
|
|
|
|
10.1*+
|
|
|
|
|
|
31.1
|
|
|
|
|
|
31.2
|
|
|
|
|
|
32.1
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
Sorrento Therapeutics, Inc.
|
|
|
|
|
|
Date:
|
May 15, 2019
|
By:
|
/s/ Henry Ji, Ph.D.
|
|
|
|
Henry Ji, Ph.D.
|
|
|
|
Chairman of the Board of Directors, Chief Executive Officer & President
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
Date:
|
May 15, 2019
|
By:
|
/s/ Jiong Shao
|
|
|
|
Jiong Shao
|
|
|
|
Executive Vice President & Chief Financial Officer
|
|
|
|
(Principal Financial Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Sorrento Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s
/
Henry Ji, Ph.D.
|
Henry Ji, Ph.D.
Chairman of the Board of Directors, Chief Executive Officer and President
(Principal Executive Officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Sorrento Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Jiong Shao
|
Jiong Shao
Chief Financial Officer
(Principal Financial Officer)
|
Date:
|
May 15, 2019
|
By:
|
/s/ Henry Ji, Ph.D.
|
|
|
|
Henry Ji, Ph.D.
|
|
|
|
Chairman of the Board of Directors, Chief Executive Officer and President
|
|
|
|
(Principal Executive Officer)
|
Date:
|
May 15, 2019
|
By:
|
/s/ Jiong Shao
|
|
|
|
Jiong Shao
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Financial Officer)
|